AIM ImmunoTech (AIM) - חוב לטווח ארוך להון

AIM ImmunoTech (AIM) minimizes capital expenditures by outsourcing drug manufacturing and testing to third-party contractors. This daily price chart illustrates the 0.01 metric. The business relies on the exclusive ownership of Ampligen, utilizing RNA technologies to combat oncology and viruses. The firm is currently focusing on its own research, limiting external interaction solely to alliances with oncology centers.

For AIM ImmunoTech, which is pursuing costly biomedical developments, the ratio of long-term debt to equity serves as an indicator of financial autonomy. This metric compares liabilities with a maturity of more than one year against the amount of shareholder equity. This allows for an assessment of the company's dependence on debt financing in the absence of operating profit. A low leverage level is critically important for startups that rely on external investments. A high ratio signals bankruptcy risks should there be a delay in scientific results.